Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 7571


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Diagnostic
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7571

License Grant
The Licensor grants the Licensee a first option to obtain a worldwide, royalty-bearing, exclusive license (with a right to sublicense) under its commercial rights in the Patent Rights in all Fields. The Licensee may exercise the Option Right upon written notice to University which is received by University within twelve  months following the Effective Date.
License Property
The intellectual property rights relate to the use of MANF and CDNF as treatment for retinal diseases, as described in University’s Patent Application number PCT/US2012/041701, “Methods of treatment for retinal diseases”.
Field of Use
The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF).

IPSCIO Record ID: 25997

License Grant
The Company entered into an Agreement with the Founders.

The Founders will receive a royalty from the gross commercial revenue of patents derived from the Company’s proprietary PhenoGuard platform technology, including patents associated with the MANF Protein and related Gene.

Field of Use
MANF is a protein compound, mesencephalic astrocyte-derived neurotrophic factor. MANF was discovered by one of the Founders,  as a drug candidate with promising therapeutic properties for treatment of syndromes such Parkinson’s Disease.

IPSCIO Record ID: 27670

License Grant
The Licensee was granted an exclusive, worldwide License with a right to subLicense to utilize certain Patent Rights of the Licensor.
License Property
The Licensed Property includes all intellectual property covering the use of mesencephalic astrocyte-derived neurotrophic factor as both a biomarker and treatment for beta cell degenerating disorders, including Wolfram syndrome, Type-1 diabetes and Type-2 diabetes.
Field of Use
Licensee may utilize the License to develop, have developed, make, have made, use, have used, import, have imported, sell, and have sold the Licenses Products and Licensed Services.

The rights granted apply to the healthcare industry.

IPSCIO Record ID: 4508

License Grant
The Licensor grants to the Licensee an exclusive, worldwide, royalty-bearing license in the Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, sell and have sold Licensed Products and Licensed Services in the Field.The Licensee may grant sublicenses of its rights.
License Property
The Invention aids in diagnosing Pancreatic Cell Disorders.

The Intellectual Property rights are as described in Licensor's invention disclosure  
”Provisional Application Entitled “ Filed 1/24/2012 – Application No. 61/590,021 PCT Application Entitled “Soluble MANF in Pancreatic Beta-Cell Disorders”Filed 1/23/2013 – Application No. PCT/US2013/022768.

Field of Use
Field means all fields, except commercial sale of research reagents covered by the Patent Rights is specifically excluded from the Field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.